Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

Daniel D. Von Hoff · Annals of Internal Medicine · 1979 · 2.4K citations

Medicine, Pharmacology, Pharmacotherapy +15

Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy

G. Michael Felker, Richard E. Thompson, Joshua M. Hare et al. · New England Journal of Medicine · 2000 · 1.7K citations · Full text

Medicine, Cardiology, Cardiac Transplantation +7

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

George W. Sledge, Donna Neuberg, Patricia Bernardo et al. · Journal of Clinical Oncology · 2003 · 707 citations

Medicine, Oncology, Pharmacology +15

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Gerald Batist, Gopal Ramakrishnan, Chandra Sekhar Rao et al. · Journal of Clinical Oncology · 2001 · 661 citations

Medicine, Oncology, Pharmacology +17

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Lyndsay N. Harris, Gerald Batist, Robert J. Belt et al. · Cancer · 2001 · 511 citations · Full text

Medicine, Oncology, Pharmacology +17